NCT06194734 - A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer | Biotech Hunter

Enrollment

490

Participants

Timeline

Start Date

February 5, 2024

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2027

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

DRUG

KC1036

KC1036 60mg QD orally, before a meal, continuous administration, 21 days as a cycle

DRUG

Irinotecan

Irinotecan intravenously administered at 130-150 mg/m2 once every 2 weeks

DRUG

Docetaxel

Docetaxel intravenously administered at 60-75 mg/m2 once every 3 weeks；

DRUG

S-1

S-1 orally administered 40-60mg Bid on Day 1 to Day 14 of every 3 weeks, 21 days as a cycle

Trial Locations (1)

RECRUITING

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors

lead

Beijing Konruns Pharmaceutical Co., Ltd.

INDUSTRY